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Peste des petits ruminants (PPR) is a viral disease of sheep and goats that is spreading through many countries
in the developing world. Work on the virus is often restricted to studies of attenuated vaccine strains or to work
in laboratories that have high containment facilities. We have created a helper cell dependent form of PPR virus
by removing the entire RNA polymerase gene and complementing it with polymerase made constitutively in a
cell line. The resultant L-deleted virus grows efficiently in the L-expressing cell line but not in other cells. Virus
made with this system is indistinguishable from normal virus when used in diagnostic assays, and can be grown
in normal facilities without the need for high level biocontainment. The L-deleted virus will thus make a positive
contribution to the control and study of this important disease.Introduction
Peste des petits ruminants (PPR) is a severe disease of
sheep and goats which has been spreading extensively
over the past two decades, and is now found widely dis-
tributed through large parts of Africa, the Middle East
and Asia; it poses an increasing threat to poor livestock
keepers, primarily in developing countries [1–4]. The dis-
ease is caused by a virus, PPR virus (PPRV), which is a
morbillivirus, related to the human pathogen measles
virus (MV), as well as other animal pathogens such as ca-
nine distemper virus (CDV) and the now-eradicated rin-
derpest virus (RPV). Control of this disease has recently
become a major international goal, marked by the adop-
tion in 2014 of a resolution by the World Organisation for
Animal Health (OIE) to establish a control programme
with a view to eventual eradication of the disease [5].
Disease control is mostly achieved through the use of
clinical or laboratory-based diagnosis coupled with vac-
cination. All the vaccines currently in use are attenu-
ated strains of PPRV [6,7]; these vaccines are effective,
though they do not provide a DIVA (Distinguishing In-
fected from Vaccinated Animals) capability, since they
provide what is essentially a totally subclinical infection
with PPRV, and the antibody signatures of vaccinated* Correspondence: michael.baron@pirbright.ac.uk
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alternative DIVA vaccines have been proposed based on
recombinant viruses [8–13], but none is yet in field use.
The most commonly used laboratory tests are those
for anti-PPRV antibodies, partly on cost grounds, and
partly because a lot of the effort in infected countries is
still on tracking the prevalence of disease through identi-
fying flocks/herd which have been exposed to the virus,
rather than acute response diagnostics on animals show-
ing clinical signs. In addition, vaccination programs are
increasingly being supported by post-vaccination serum
surveillance to measure the effectiveness of the local
vaccination process. Although there are still laboratories
using agarose gel immunodiffusion (AGID) techniques,
the primary method of testing for anti-PPRV antibodies is
competition ELISA (cELISA), and the antibodies tested
for are either those recognising the viral nucleocapsid pro-
tein (N) [14,15], in which the ELISA antigen is a bacter-
ially expressed protein, or those recognising the viral
surface glycoprotein H [16,17], where whole virus is used
as the ELISA antigen. The latter system presents a prob-
lem in the need to grow and purify live virus, even if it is
only a vaccine strain of the virus. In many countries, this
requires a containment laboratory for the virus culture,
and continued application of biosecurity restrictions, in-
cluding restrictions on the transport of the ELISA kits,article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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e.g. with binary ethylenimine (BEI). For larger scale and
simplified production of antigen for ELISA, it would be
useful to be able to prepare a suitable antigen without the
need for actual virus. The H protein requires mammalian
glycosylation for proper folding, so baculovirus-expressed
protein is not adequate. We have therefore sought to create
a biosafe system to produce virus-like particles (VLPs)
which would appear as virus in diagnostic tests and which
could be produced in good yield. We have achieved this by
deleting an essential gene from the PPRV genome and pro-
viding the required protein in trans in a helper cell line.
In our previous studies, it was shown that removing
the P gene from a morbillivirus genome and providing
the P protein from a helper cell line can lead to the pro-
duction of suitable VLPs, but in too low yield for practical
use, since the P-expressing cell line cannot synthesize the
amount of P protein that is required to support normal
virus replication and assembly [18]; the P gene is, in any
event, a complex system in morbilliviruses, being also re-
quired for the production of accessory proteins V and C,
both of which are required for optimal virus replication
[18–21]. We show here that a PPRV genome lacking
the entire gene for the viral polymerase (L) protein
grows to near-normal levels in a cell line expressing the
L protein, generating VLPs that act as a good antigen
in the cELISA, as well as acting as a model virus for de-
tection by PCR-based techniques. The VLPs cannot
replicate in other cell lines.
Materials and methods
Cells and viruses
Vero cells expressing the canine version of the morbilli-
virus receptor SLAM (Signalling Lymphocyte Activation
Molecule) (Vero-Dog-SLAM, VDS) were obtained from
Dr Paul Duprex, then at Queen’s University Belfast, N.
Ireland, and maintained in Dulbecco’s modified Eagle’s
medium containing 25 mM HEPES buffer, penicillin (100
U/mL), and streptomycin (100 μg/mL) (DMEM) contain-
ing 10% foetal calf serum (FCS). Zeocin was included at 0.1
mg/mL to maintain selection for SLAM expression. PPRV
Nigeria 75/1 vaccine strain [6] and recombinant PPRV
rPPRV-GFP [22] were propagated and titrated in VDS
cells. Titres were determined as the 50% tissue culture in-
fectious dose (TCID50), calculated by the method of Spear-
man and Kärber [23]. Titres of preparations of PPRV-del-L
were determined in VDS-L cells, while titres of complete
PPRV were determined in VDS cells.
Transfections and infections of cultured cells
VDS cells or VDS-L cells were plated at 4 × 104 cells per
well in 12-well plates or 105 cells per well in 6-well
plates. For immunofluorescence studies, the wells con-
tained sterile glass coverslips (10mm in diameter). Thecells were allowed to attach and were infected 6-18 h
after plating at a multiplicity of infection (moi) as indi-
cated for each experiment. For infection studies, virus
inocula were removed after one hour, the cells washed
once with phosphate buffered saline and fresh medium
added. Cells were transfected using TransIT-LT1 accord-
ing to the manufacturer’s instructions, using 3 μL trans-
fection reagent per μg DNA. At the indicated time after
transfection, cells were fixed for immunofluorescence
staining and confocal microscopy [22], or dissolved in
SDS-PAGE sample buffer, or subjected to a freeze-thaw
cycle to release progeny virus.
Recombinant PPRV del-L
The PPRV genomic clone (pPPRV-GFP) and the proced-
ure for recovering live virus from plasmids was as previ-
ously published [22]. The PPRV-del-L genome was
constructed by removing bases 10031-16690 from the
PPRV-GFP cDNA, i.e. the entire sequence from 26 bases
after the H open reading frame (ORF) to 5 bases after
the L ORF. The sequences removed include the H
gene stop signal, the intergenic trinucleotide, the L
gene start signal and the whole L ORF (a total of
6660 bases). This genome manipulation was carried
out using Gibson assembly [24] of two large PCR
products derived from the PPRV-GFP plasmid. The two
fragments were generated using primer pairs Del-L_F1
[TGCAACCATCGCTCGAGCAAGTGATACATCTGCC
CCCTTCTC] with Del-L_R1 [GATTCTTGTGTCAAC
CCCTGGA] and Del-L_F2 [TCCAGGGGTTGACACA
AGAATC] with Del-L_R2 [GAGAAGGGGGCAGATG
TATCACTTGCTCGAGCGATGGTTGCA]. The entire
sequence of the resulting PPRV-del-L genome was
checked.
Creation of the helper cell line
To create the cell line expressing PPRV L, the exact L
ORF, without any transcription control sequences (i.e. no
gene start, gene stop or untranslated region), was fused
downstream of the V5 epitope tag and cloned under the
control of the promoter in pCAGGS (pCAGSS-V5-L). A
large section of this plasmid, consisting of the pCAGGS
promoter and intron and the V5-L ORF, was then inserted
into plasmid 5’-PTK-3’ [25], upstream of the IRES-driven
puromycin resistance marker in that vector. To do this, the
En-2 splice acceptor was removed from 5’-PTK-3’ and re-
placed with a short multiple cloning site (XhoI/SgfI/AflII/
SbfI/NheI/MfeI) to give pPB-MCS-IPUR. The CAGGS-V5-
L construct from pCAGGS-V5-L was then inserted into
pPB-MCS-IPUR to give pPB-V5-PPRV-L. The plasmid
pPB-V5-PPRV-L was transfected into VDS by standard
techniques along with plasmid pCyL43 encoding the trans-
posase [26] and the cells subjected to puromycin selection
through 3 passages to create the VDS-L cell line.
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RNA was extracted from cells using the Qiagen RNeasy
mini kit. cDNA was synthesised using Superscript II re-
verse transcriptase with oligo(dT)-anch [27] as the primer.
Real-time quantitative PCR of PPRV N mRNA or host cell
L13A mRNA was carried out essentially as previously de-
scribed [18,27], using a set of primers recognising the
PPRV N gene and optimised for SYBR Green-based qPCR
(NF2b:CGGGTTGACCTTTGCATCA and NREVb: CTT
TGTTGTGTGTATTTAACCCACCTT). Confocal mi-
croscopy was performed as previously described [22].
Mouse anti-V5 tag was obtained from AbD Serotec and
AlexaFluor 568 anti-mouse IgG was from Life Tech-
nologies. All images were taken by sequential scanning
and the resulting separate colour images overlayed in
Photoshop. cELISA antigen was prepared as previously
described [16]. SDS-PAGE and Western blots were car-
ried out as previously described [28], except that the
Western blot transfer was performed using a TransBlot
SD Semi Dry Electrophoretic Transfer Cell (Bio-Rad)
and Bjerrum and Schafer-Nielsen transfer bufferFigure 1 Expression of functionally active PPRV L protein. A VDS cells
and cultured for 48 h. After lysis of the transfected cells, expressed protein
tag. B Cells (VDS or VDS-L) in 6-well dishes were transfected with the indicate
to 1 freeze-thaw cycle to release infectious virus and the clarified supernatant u
and the expression of virally-encoded GFP analysed by SDS-PAGE and Western
were lysed directly in SDS-PAGE sample buffer and analysed by SDS-PAGE an
encoding the L protein was included.(48 mM Tris, 39 mM glycine, 37.5 mg/L SDS, 20%
methanol, pH 9.2) [29]. Statistical analysis was per-
formed in Minitab v17.
Results
In previous work, it was found that a recombinant
rinderpest virus in which the L protein had an amino-
terminal HA tag was fully functional (Baron, M.D., un-
published). It seemed likely that insertion of an epitope
tag at the amino-terminus of a morbillivirus L protein
does not interfere with its function, so a PPRV L protein
expression construct was created with the V5 epitope
tag at this position. Despite the large size of the L pro-
tein, significant amounts of full-length L protein were de-
tected in cells transfected with this construct (Figure 1A).
In addition, the V5-L construct was equally effective in
supporting the rescue of PPRV from the plasmid copy of
the genome as was the original pCAGGS-L (Figure 1B),
confirming that it is functional as the viral polymerase.
Since the V5-L was fully functional, the VDS-L helper
cell line was created using this construct. VDS cells werewere transfected with the indicated plasmid (2 μg) in 6-well dishes
s were analysed by SDS-PAGE and Western blot using mouse anti-V5
d plasmids and incubated for 8 days. The transfected cells were subjected
sed to infect fresh VDS or VDS-L cells. After 7 days, the cells were harvested
blot. Actin was used as a loading control. C VDS or VDS-L cells (~4 × 105)
d Western blot using mouse anti-V5 tag. D As B, except that no plasmid
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been, in our hands, the best cell line for growing PPRV,
either wild-type or vaccine strains. The presence of the
morbillivirus receptor (SLAM) ensures that virus growth
leads to rapid production of large syncytia, which are
easy to detect and characteristic of virus replication and
viral glycoprotein expression. Normal methods for creat-
ing cell lines expressing extra proteins by transfecting
with the plasmid of interest, in linear or circular form,
along with a plasmid encoding an antibiotic resistance
marker, were ineffective. Resistant cells could be isolated,
but they either did not express any V5 tag-bearing pro-
tein at all or the protein detected was a severely trun-
cated form of the L protein. Since a problem with these
methods is that they rely on random recombination
events of genomic DNA with the plasmids in question,
it appeared that the L sequence was long enough to
make it highly probable that such an event would occur
within its sequence, or that of the governing promoter.
We therefore sought to carry out a directed insertion of
a defined expression cassette using the PiggyBac trans-
posase system [30]. This method was very effective. The
resultant cell line was isolated at the first attempt and
was found to express an L protein that was the same size
as the original (Figure 1C), and was able to support res-
cue of rPPRV-GFP when the cell line was the only
source of L protein (Figure 1B), showing that the cell
line-expressed L protein was functional.
A corresponding version of pPPRV-GFP was then cre-
ated which lacked the L gene. In order to preclude any
possibility of the full virus being recreated by recombin-
ation with L sequences in the cell line, we deleted not
only the L ORF, but also all the transcriptional controlFigure 2 PPRV-del-L requires helper cell line. VDS or VDS-L cells were inf
Cells were fixed and stained with mouse anti-V5 tag and AlexaFluor 568-conjug
were taken by sequential scanning.sequences required for its transcription by the viral
RNA-dependent RNA polymerase. Correspondingly, the
construct inserted into the cell line genome contains
only the L protein ORF, so there is no sequence com-
mon to the L protein mRNA and the cut-down PPRV
genome. The PPRV-del-L genome could be rescued (as
evidenced by expression of GFP and the viral glycopro-
teins and development of cytopathic effect (cpe)) in
VDS-L cells, but not in the normal VDS cells (Figure 1D).
The resultant virions could be harvested, titrated and pas-
saged as for the parental virus, but only on VDS-L cells;
no replication was seen in VDS cells (Figure 2).
Because it is a normal constituent of the virion, a small
amount of the L protein was found in the PPRV-del-L
VLPs produced in VDS-L cells. L protein carry-over was
sufficient that a low level of GFP expression could be de-
tected in VDS cells infected with PPRV-del-L, though
only if the infection was carried out at a relatively high
multiplicity of infection (moi) (Figure 3). In order to be
sure that no PPRV-del-L was growing in cells without
the L protein, serial passage of the VLPs on VDS cells
was carried out in order to try to amplify any functional
virion. No cpe was seen during these serial passages, nor
was there any sign of GFP expression. Quantitative RT-
qPCR was used to assay viral mRNA from each one of
the passages, and showed only the expected decay of the
viral RNA present in the initial inoculum.
No evidence for replication of the viral genome was
seen in VDS cells, even with repeated passage (Figure 4).
Note that for PPRV, as for other morbilliviruses, the
virus inoculum is not pure virus, and the original inocu-
lum always contains significant non-infectious viral gen-
ome and even some viral mRNA; this means that RNAected with PPRV-GFP or PPRV-del-L at moi = 0.01 and incubated for 48 h.
ated goat anti-mouse IgG. Nuclei were stained with DAPI. Confocal images
Figure 3 Protein expression from PPRV-del-L after infection at higher moi. Cells were infected with PPRV-del-L at moi = 0.5. At 48 hours post
infection, cells were fixed and stained as in Figure 2. Confocal images were taken by sequential scanning. Fields showing infection and protein expression
in VDS and VDS-L are shown.
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fected cells harvested at t = 0, always gives a positive sig-
nal in RT-qPCR (Figure 4).
Cells infected with live rPPRV-GFP show a steadily in-
creasing amount of viral genome with time, reflecting
viral replication (Figure 5). However, if the initial inocu-
lum is heat-inactivated PPRV, the content of viral gen-
ome simply decays over time, with no indication of
replication (Figure 4). The pattern seen with PPRV-del-L
in VDS cells was similar to that seen with inactivated
PPRV.
Multi-step growth curves were performed to compare
the growth kinetics of the parental and del-L viruses.
These studies were carried out in VDS-L cells, so thatFigure 4 PPRV-del-L behaves as heat-inactivated PPRV. VDS cells were
heat-inactivated (2 h at 58 °C) (inactPPRV) at a nominal moi of 0.5. After r
RNA or cultured for 6 days (p1). After 6 days, the infected cells were subjected
the supernatant passaged to fresh cells (p2). This procedure was then repeated
in each sample (A); Vero cell L13A mRNA was used as control for the recovery
observed from duplicate PCRs from each of duplicate wells).the same cell line was used for the two viruses. It was
found that the PPRV del-L virus grew similarly to nor-
mal virus in these cells (Figure 5), although still slightly
slower than the normal virus (2-way ANOVA, p < 0.05
for growth measured as either virus (Figure 5A) or viral
RNA (Figure 5B)). Interestingly, the normal PPRV grew
slightly worse in the cells expressing endogenous L pro-
tein than in parental VDS cells (compare Figure 5A with
Figure 3A of [22] and Figure 2A of [18]). This observation
is in accord with the observation that virus-encoded
GFP expression from full PPRV is lower in VDS-L cells
than in VDS cells (Figure 2). This apparent defect in
virus replication in the presence of excess L protein may
reflect previous observations that the correct ratio of theinfected with PPRV-del-L (PPRVdelL) or PPRV that had been
emoving unattached virus, duplicate wells were harvested immediately for
to 1 freeze-thaw cycle, the cell pellet harvested for RNA, and one third of
(p3). RT-qPCR was used to determine the relative amount of viral mRNA
of RNA from each sample (B). Results are expressed as 40-(mean Ct value
Figure 5 Comparison of growth and antigenicity of PPRV-del-L and full PPRV. VDS-L cells in 6-well plates were infected with PPRV-GFP or
PPRV-del-L at moi = 0.01. Duplicate wells were harvested at 0, 1, 2, 3, 4 and 5 days post infection, subjected to one freeze-thaw cycle and the released
virus titrated (A). RNA was extracted from the cell pellets and viral (genome+mRNA) assayed by RT-qPCR (B). C VDS-L cells were infected with PPRV-del-L
(moi = 0.01) in 175cm2 flasks and cultured for 5 days. Virus antigen was prepared and used in the PPRV-H cELISA (BDSL) according to the manufacturer’s
instructions. A set of samples known to be positive (% inhibition >50%) and negative (% inhibition <50%) were assayed in parallel cELISA tests using
either the PPRV antigen provided with the kit or the antigen made from PPRV-del-L. All sera were assayed in duplicate in each test and the mean %
inhibition obtained with each antigen plotted in the graph. The set of individual mean values for each serum were compared using a paired t-test: the
mean difference was not significantly different from zero (p = 0.081). The regression line had a slope of 0.99 ± 0.02 (± S.E.) and an intercept of 1.81 ± 1.34.
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paramyxovirus genomes [31,32].
Antigen for the PPRV cELISA was prepared from
PPRV-del-L grown on VDS-L cells and its performance
in the assay compared with that of the antigen distrib-
uted with H protein-specific cELISA kit; the results were
essentially identical (Figure 5C), showing that the VLPs
produce an antigen which behaves exactly like normal
antigen in cELISA, while the VLPs can act as a template
for PCR tests.
Discussion
In our previous work [18], we showed that deletion of
the morbillivirus P protein coding sequence produced a
replicon that could replicate only in cell lines expressing
the P protein, although even then with greatly reduced
replication relative to the intact virus. The viruses lack-
ing the P protein coding sequence were completely
dependent on the helper cell line for transcription and
replication. In the work presented here, we have shownthat a replicon lacking the L (polymerase) gene (PPRV-
del-L) can replicate in a cell line expressing the L protein
(VDS-L), and with efficiency close to that of the parental
virus. This replicon is unable to replicate in any other
cell, since it lacks the L gene in its entirety. Repeated
blind passage of the VLPs produced by PPRV-del-L in
cultured cells showed no replication of the replicon gen-
ome (as assessed by RT-qPCR).
A key question in considering the biosafety of the
PPRV-del-L is whether there is any possibility of the
virus recovering its ability to replicate through the re-
covery of its polymerase gene or the gene for a poly-
merase that would fulfil the same function. Replication
and transcription of PPRV, as with all nonsegmented
negative-strand RNA viruses (NNSRVs), take place ex-
clusively in the cytoplasm of the infected cell. Because
the NNSRVs all co-transcriptionally encapsidate their
genome and antigenome RNAs, naked viral RNAs
(other than mRNAs) are not found in the cytoplasm. In
addition, the template for the viral RNA polymerase is
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sequences (the 5’ and 3’ terminal 120 bases), and never
naked RNAs, whether viral mRNAs or derived from the
host genome. For this reason, recombination is not
found in this group of viruses in nature (reviewed in
[33]). There is one published example of the creation of
a chimeric NNSRV, which was done in culture and
under specific selection for recombinant viruses [34];
in that particular case it was a combination of two dif-
ferent strains of respiratory syncytial virus. There is
also some indirect evidence from analysis of sequences
in the database that recombination between strains of
the same virus has occurred in nature [35–41]; there is
no evidence either in nature or in culture of recombin-
ation between dissimilar NNSRVs or between NNSRV
genomes and cellular RNAs.
Given these findings, it is clearly possible for PPRV-
del-L to recover its L gene through recombination with
a natural PPRV virus. In this case, of course, there is
already live PPRV in the system, so this circumstance
would not introduce an additional hazard. If the donor
is itself a wild type virus, there is already pathogenic
virus present. The del-L virus is based on the fully atten-
uated vaccine strain of PPRV. The stability of this vac-
cine through several decades of use in the field shows
that it has attenuating mutations throughout the gen-
ome, as was found for the Plowright vaccine [42,43], and
indeed the P, F, H and N proteins of the vaccine strain
all show extensive differences from those of wild type vi-
ruses isolated at the same time and geographical area,
while the promoters in the vaccine show changes to
bases that are conserved in all known wild type viruses.
Donation of L from a different PPRV vaccine will not
therefore result in a chimera that has become virulent.
Recombination between the del-L virus and a different
PPRV virus would in any event require coinfection of
the same cells; since PPRV is restricted to containment
laboratories in countries where the virus is not endemic,
use of the del-L system in non-containment laboratories
does not pose a threat.
Another possibility is that PPRV del-L could gain an L
gene from another (non-contained) morbillivirus. This
would require recombination between the PPRV genome
and that of another morbillivirus (e.g. CDV, measles
virus). There is no evidence from nature of recombin-
ation having occurred between two different NNSRVs
which has given rise to a viable chimeric virus. This may
be because such recombination has to occur at very
similar sequences, as is known to be the case in pox
virus recombination [44]. Alternatively, it may be be-
cause co-evolution of the viral proteins has led to in-
compatibilities between proteins from different, even if
closely related, viruses, for example the finding that the
surface glycoproteins (F and H) of PPRV will worktogether, but not in any heterologous pair with the H
and F proteins of RPV [45]. More importantly, the N, P
and L proteins of morbilliviruses, which together form
the transcription/replication complexes, only work ef-
fectively when all three come from the same virus [46].
A PPRV that had acquired the L gene of CDV from rep-
licating CDV would therefore have a non-functional N/
P/L combination. Whatever the underlying biochemistry,
the evidence over hundreds of years of cocirculation of
different morbilliviruses (and other paramyxoviruses) is
that recombination between genomes of different viruses
does not occur, and the PPRV-del-L will not acquire a
functional polymerase through recombination with a dif-
ferent morbillivirus.
A third risk might be that the del-L virus could re-
acquire the L gene from the helper cell line. As mentioned
previously, there is no recorded case of a NNSRV picking
up genetic material from a host mRNA, making it unlikely
that it would happen in this case. In any event, the entire
L gene transcription unit is removed from the del-L con-
struct (including the gene transcription start and end se-
quences), while the helper cell contains only the L protein
ORF, so that even if recombination were to occur between
viral genome and cell mRNA, vital parts of the virus
would be missing.
While we have not carried out this study, it is likely
that the PPRV-del-L construct could be replicated by an-
other morbillivirus, though not very well. A related con-
struct based on two defective measles virus genomes has
been propagated [47], though the resultant virus did not
grow well, presumably because the minimum infectious
unit needed to contain one of each genome. It was only
maintained because both genomes were defective and
had to support each other in trans. Co-infection of a cell
by both PPRV-del-L and another morbillivirus (e.g.
CDV) would lead to replication of the PPRV-del-L gen-
ome and transcription of its genes. However, this is es-
sentially the same as the CDV replicating in the
presence of a large deletion DI (defective interfering par-
ticle). Replication of the CDV would be decreased, and
the “DI” still could not replicate independently. PPRV as
such would not be recreated. Such a mixed infection
could conceivably give rise to a sort of two-segmented
pathogenic virus containing both the full genome of the
non-contained morbillivirus and that of the PPRV-del-L
replicon, but such a mixture would be under the usual
selective pressure to lose the "DI" component.
Our results in morbilliviruses are completely in line
with work done with another NNSRV, vesicular stoma-
titis virus (VSV), which has been developed in several la-
boratories as a gene delivery tool by removing the gene
for the viral G protein; the VSV G protein functions
both for viral attachment and fusion with the target cell.
The resultant cut down viral genome, with or without
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(e.g. influenza HA, luciferase) could be replicated by pro-
viding the G protein in a helper cell line, which is used for
growing stocks of resultant VLPs, e.g. [48–58]. This type
of VSV construct is generally classified as BSL1 e.g. [49],
as transmissibility is entirely dependent on the helper cell
line’s provision of the G protein. A similar series of con-
structs has been developed based on Sendai virus (SeV),
where either the F or M genes, or both, are deleted e.g.
[59–66]. These constructs have been used for various
functional studies as well as vaccine vector studies, and
are generally recognised as nontransmissible (though risk
assessment depends on the nature of the additional gene
inserted into the constructs, if any).
In summary, we have created a version of a highly re-
stricted virus which can only replicate in a defined
helper cell line. The resultant construct is therefore safe
to use and manufacture out of containment. It can be a
safe source not only of antigen for diagnostic kits, but
for validation of diagnostic assays (PCR, icELISA, VNTs)
in laboratories which have restrictions on admitting live
PPRV (even if subsequently chemically inactivated), or
PPRV from other countries (e.g. international ring trials).
In addition, the system described could be used by la-
boratories wishing to study replication and assembly of
PPRV but lacking appropriate high containment facil-
ities. The system has been approved by the UK Health
and Safety Executive for use at BSL 1.
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